Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...

In the Spanish city of Murcia, an explosion occurred at the plant of the German company Rheinmetall, which manufactured ...

One of the standout projects making waves in this space is Monsta Mash, a GameFi ecosystem that is drawing significant attention from large investors due to its incredibly low entry price of $0.00365.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

From a custom bourbon experience to Bold Picks by Eli Manning, here is what's happening on Kentucky's bourbon scene this ...

Russian-born ice skating coaches and former world champions Yevgenia Shishkova and Vadim Naumov were aboard the American ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...